Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

Research Institute of the McGill University Health Centre

$1,116,900.00

Role of methyl-CpG-binding domain protein 2 (Mbd2) in breast cancer development, progression and metastasis

EF 2022-23

Résumé
Breast cancer metastasis to distant organs in general and to the skeleton in particular are a major cause of cancer associated morbidity and mortality. These patients are generally in advanced stages when no effective therapies are available. Cancer initiation and progression is regulated by genes which activate key intracellular signaling pathways. Our genes are regulated by a set of chemical marks on DNA called DNA methylation. Interestingly, we identified a protein methyl-CpG-binding domain protein 2 (Mbd2) that is responsible for this loss of DNA methylation. Inhibition of Mbd2 expression in cell culture and in animal models of breast cancer results in blocking the expression of cancer promoting genes. In this study different mouse models of breast cancer metastasis as well as human metastasizing breast cancer cells will be implanted in mice to test the hypothesis that Mbd2 depletion by genetic and molecular methods blocks breast cancer growth and metastasis. The study will examine in depth the underlying mechanism of action of Mbd2 in cancer which will lead to the future development of Mbd2 targeted therapies for breast and other common cancers.
Programme
Project Grant
Emplacement
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
479148
Name
Rabbani Shafaat A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Pharmacology & Toxicology
Projecttitle
Role of methyl-CpG-binding domain protein 2 (Mbd2) in breast cancer development, progression and metastasis
Programtype2
Operating Grants
Orgnameinp2
Research Institute of the McGill University Health Centre
Cihramount2
$1,116,900
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Breast Cancer; Dna Methylation; Mouse Models; Transgenic Mice; Tumour Metastasis
Abstract
Breast cancer metastasis to distant organs in general and to the skeleton in particular are a major cause of cancer associated morbidity and mortality. These patients are generally in advanced stages when no effective therapies are available. Cancer initiation and progression is regulated by genes which activate key intracellular signaling pathways. Our genes are regulated by a set of chemical marks on DNA called DNA methylation. Interestingly, we identified a protein methyl-CpG-binding domain protein 2 (Mbd2) that is responsible for this loss of DNA methylation. Inhibition of Mbd2 expression in cell culture and in animal models of breast cancer results in blocking the expression of cancer promoting genes. In this study different mouse models of breast cancer metastasis as well as human metastasizing breast cancer cells will be implanted in mice to test the hypothesis that Mbd2 depletion by genetic and molecular methods blocks breast cancer growth and metastasis. The study will examine in depth the underlying mechanism of action of Mbd2 in cancer which will lead to the future development of Mbd2 targeted therapies for breast and other common cancers.
Competitiondate
202303
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Rabbani, Shafaat A
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,116,900~ $0~